ArticleBrain : a journal of neurology2021
Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder.
Article in Brain : a journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01453127 (DaTSCAN Imaging in Aging and Neurodegenerative Disease), which is not on this map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DaTSCAN Imaging in Aging and Neurodegenerative Disease
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Neuroanatomical and clinical correlates of prodromal dementia with Lewy bodies: a systematic literature review of neuroimaging findings.Journal of neurology · 2024Pooled it
- Post-Traumatic Stress Disorder and Risk of Degenerative Synucleinopathies: Systematic Review and Meta-Analysis.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2023Pooled it
- Clinical markers of disease progression in the prodromal to overt alpha-synucleinopathy continuum.Brain : a journal of neurology · 2026Article
- Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Stage-specific polysomnographic and MRI markers across phenoconversion in isolated REM sleep behavior disorder.Journal of neurology · 2026Observational
- Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum.European journal of nuclear medicine and molecular imaging · 2026Article
- Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.Current neurology and neuroscience reports · 2026Review
- Spatio-temporal gait signatures across prodromal and early Parkinson's disease in two independent cohorts.Scientific reports · 2026Article
- Article
- Neuroimaging in multiple system atrophy: clinical implications and novel developments.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Longitudinal resting-state EEG-based modeling predicts phenoconversion and delineates heterogeneity in isolated REM sleep behavior disorder.Research square · 2026Article
- MRI susceptibility map weighted imaging (SMWI) as a neurodegeneration biomarker in the prodromal to overt alpha-synucleinopathy continuum.Journal of Parkinson's disease · 2026Article
- Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.Brain sciences · 2026Article
- Susceptibility and diffusion MRI biomarkers predict development of Parkinsonism in iRBD.NPJ Parkinson's disease · 2025Article
- REM Sleep Behavior Disorder as a Prodromal Synucleinopathy: Updates on Clinical and Laboratory Biomarkers, and Implications for Neuroprotective Trials.Current neurology and neuroscience reports · 2025Review
- Modeling Midbrain and Brainstem Neuromelanins to Characterize Metal Binding and Associated MRI Contrast in Parkinson's and Alzheimer's Diseases.Angewandte Chemie (International ed. in English) · 2025Article
- Video analysis reveals early signs of Bradykinesia in REM sleep behavior disorder and Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Unveiling Cortical Criticality Changes along the Prodromal to the Overt Continuum of Alpha-Synucleinopathy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- EEG alpha peak frequency: cognitive impairment severity marker in isolated REM sleep behavior disorder.NPJ Parkinson's disease · 2025Article
- The Many Faces of REM Sleep Behavior Disorder. Providing Evidence for a New Lexicon.European journal of neurology · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 16 institutions in 6 countries.
Funding
Abstract
This is an international multicentre study aimed at evaluating the combined value of dopaminergic neuroimaging and clinical features in predicting future phenoconversion of idiopathic REM sleep behaviour (iRBD) subjects to overt synucleinopathy. Nine centres sent 123I-FP-CIT-SPECT data of 344 iRBD patients and 256 controls for centralized analysis. 123I-FP-CIT-SPECT images were semiquantified using DaTQUANTTM, obtaining putamen and caudate specific to non-displaceable binding ratios (SBRs). The following clinical variables were also analysed: (i) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale, motor section score; (ii) Mini-Mental State Examination score; (iii) constipation; and (iv) hyposmia. Kaplan-Meier survival analysis was performed to estimate conversion risk. Hazard ratios for each variable were calculated with Cox regression. A generalized logistic regression model was applied to identify the best combination of risk factors. Bayesian classifier was used to identify the baseline features predicting phenoconversion to parkinsonism or dementia. After quality check of the data, 263 iRBD patients (67.6 ± 7.3 years, 229 males) and 243 control subjects (67.2 ± 10.1 years, 110 males) were analysed. Fifty-two (20%) patients developed a synucleinopathy after average follow-up of 2 years. The best combination of risk factors was putamen dopaminergic dysfunction of the most affected hemisphere on imaging, defined as the lower value between either putamina (P < 0.000001), constipation, (P < 0.000001) and age over 70 years (P = 0.0002). Combined features obtained from the generalized logistic regression achieved a hazard ratio of 5.71 (95% confidence interval 2.85-11.43). Bayesian classifier suggested that patients with higher Mini-Mental State Examination score and lower caudate SBR asymmetry were more likely to develop parkinsonism, while patients with the opposite pattern were more likely to develop dementia. This study shows that iRBD patients older than 70 with constipation and reduced nigro-putaminal dopaminergic function are at high risk of short-term phenoconversion to an overt synucleinopathy, providing an effective stratification approach for future neuroprotective trials. Moreover, we provide cut-off values for the significant predictors of phenoconversion to be used in single subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.